Sector
Healthcare
Industry
Biotechnology
Employees
108
First IPO Date
December 11, 2020
| Name | Title | Pay | Year Born |
| Laurent Levy | Co-Founder, President of the Executive Board & Chief Executive Officer | 968,526 | 1973 |
| Anne-Juliette Hermant | Chief People Officer & Member of Executive Board | 475,048 | 1974 |
| Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board | 688,010 | 1974 |
| Louis Kayitalire | Chief Medical Officer & Member of Executive Board | 691,407 | 1959 |
| Brandon Owens | Vice President of Strategic Marketing & Corporate Communication | 0 | N/A |
| Anne-Sophie Lariviere | Chief Product Innovation & Delivery Officer | 0 | N/A |
| Margaret Galluzzi | Vice President & Global Head of Clinical Operations | 0 | N/A |
| Earl J. Bergey | Co-Founder | 0 | 1955 |
| Leonard A. Farber | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board | 0 | N/A |
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.